Details of the Drug

General Information of Drug (ID: DM2QHZU)

Drug Name
Sulindac
Synonyms
Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [1]
Bursitis N.A. Approved [1]
Osteoarthritis FA00-FA05 Approved [1]
Rheumatoid arthritis FA20 Approved [2]
Colon cancer 2B90.Z Investigative [1]
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 356.4
Logarithm of the Partition Coefficient (xlogp) 3.4
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption
The absorption of drug is approximately 90% following oral administration []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
88% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The renal clearance of drug is 68.12 +/- 27.56 mL/min []
Elimination
1% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 7.8 hours [5]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 16.0325 micromolar/kg/day [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0028 mg/mL [3]
Chemical Identifiers
Formula
C20H17FO3S
IUPAC Name
2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
Canonical SMILES
CC\\1=C(C2=C(/C1=C\\C3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O
InChI
InChI=1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
InChIKey
MLKXDPUZXIRXEP-MFOYZWKCSA-N
Cross-matching ID
PubChem CID
1548887
ChEBI ID
CHEBI:9352
CAS Number
38194-50-2
DrugBank ID
DB00605
TTD ID
D0Z5IU
VARIDT ID
DR00715
ACDINA ID
D00644
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aldose reductase (AKR1B1) TTFBNVI ALDR_HUMAN Inhibitor [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Gene/Protein Processing [9]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Gene/Protein Processing [10]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Gene/Protein Processing [10]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Gene/Protein Processing [10]
Allograft inflammatory factor 1-like (AIF1L) OTDEOB80 AIF1L_HUMAN Gene/Protein Processing [11]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Gene/Protein Processing [11]
Angiopoietin-related protein 3 (ANGPTL3) OTCD5Z9W ANGL3_HUMAN Gene/Protein Processing [9]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Gene/Protein Processing [12]
Ankyrin repeat domain-containing protein 11 (ANKRD11) OTV0V70M ANR11_HUMAN Gene/Protein Processing [11]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Protein Interaction/Cellular Processes [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Sulindac
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Sulindac and Sulfasalazine. Rheumatoid arthritis [FA20] [13]
Dexamethasone DMMWZET Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Dexamethasone. Rheumatoid arthritis [FA20] [14]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Sulindac and Leflunomide. Rheumatoid arthritis [FA20] [15]
Coadministration of a Drug Treating the Disease Different from Sulindac (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Sulindac and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [16]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Sulindac and Repaglinide. Acute diabete complication [5A2Y] [17]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Sulindac and Glibenclamide. Acute diabete complication [5A2Y] [17]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Sulindac and Tolazamide. Acute diabete complication [5A2Y] [17]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Sulindac and Nateglinide. Acute diabete complication [5A2Y] [17]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Sulindac and Glipizide. Acute diabete complication [5A2Y] [17]
Inotersen DMJ93CT Major Increased risk of bleeding by the combination of Sulindac and Inotersen. Amyloidosis [5D00] [18]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Sulindac and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [19]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Sulindac and Cilostazol. Arterial occlusive disease [BD40] [20]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Budesonide. Asthma [CA23] [14]
Ofloxacin DM0VQN3 Moderate Additive CNS stimulant effects by the combination of Sulindac and Ofloxacin. Bacterial infection [1A00-1C4Z] [21]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Sulindac and Kanamycin. Bacterial infection [1A00-1C4Z] [22]
Trovafloxacin DM6AN32 Moderate Additive CNS stimulant effects by the combination of Sulindac and Trovafloxacin. Bacterial infection [1A00-1C4Z] [21]
Sparfloxacin DMB4HCT Moderate Additive CNS stimulant effects by the combination of Sulindac and Sparfloxacin. Bacterial infection [1A00-1C4Z] [21]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Sulindac and Streptomycin. Bacterial infection [1A00-1C4Z] [22]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Sulindac and Gemifloxacin. Bacterial infection [1A00-1C4Z] [21]
Norfloxacin DMIZ6W2 Moderate Additive CNS stimulant effects by the combination of Sulindac and Norfloxacin. Bacterial infection [1A00-1C4Z] [21]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Sulindac and ABT-492. Bacterial infection [1A00-1C4Z] [21]
Gentamicin DMKINJO Moderate Increased risk of nephrotoxicity by the combination of Sulindac and Gentamicin. Bacterial infection [1A00-1C4Z] [22]
Netilmicin DMRD1QK Moderate Increased risk of nephrotoxicity by the combination of Sulindac and Netilmicin. Bacterial infection [1A00-1C4Z] [22]
Levofloxacin DMS60RB Moderate Additive CNS stimulant effects by the combination of Sulindac and Levofloxacin. Bacterial infection [1A00-1C4Z] [21]
Tobramycin DMUI0CH Moderate Increased risk of nephrotoxicity by the combination of Sulindac and Tobramycin. Bacterial infection [1A00-1C4Z] [22]
Lomefloxacin DMVRH9C Moderate Additive CNS stimulant effects by the combination of Sulindac and Lomefloxacin. Bacterial infection [1A00-1C4Z] [21]
Etidronic acid DM1XHYJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Etidronic acid. Bone paget disease [FB85] [23]
Risedronate DM5FLTY Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Risedronate. Bone paget disease [FB85] [23]
Alendronate DMY2KX9 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Alendronate. Bone paget disease [FB85] [23]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Sulindac and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [24]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Sulindac and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [20]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Sulindac and Iodipamide. Cholelithiasis [DC11] [25]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Sulindac and Levomilnacipran. Chronic pain [MG30] [26]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Sulindac and Regorafenib. Colorectal cancer [2B91] [18]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Sulindac and Drospirenone. Contraceptive management [QA21] [27]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Sulindac and Methoxyflurane. Corneal disease [9A76-9A78] [18]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Sulindac and Ardeparin. Coronary thrombosis [BA43] [28]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Sulindac and Danaparoid. Deep vein thrombosis [BD71] [28]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Sulindac and Rivaroxaban. Deep vein thrombosis [BD71] [29]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Sulindac and Sertraline. Depression [6A70-6A7Z] [26]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Sulindac and Vilazodone. Depression [6A70-6A7Z] [26]
Paroxetine DM5PVQE Moderate Increased risk of bleeding by the combination of Sulindac and Paroxetine. Depression [6A70-6A7Z] [26]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Sulindac and Vortioxetine. Depression [6A70-6A7Z] [26]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Sulindac and Milnacipran. Depression [6A70-6A7Z] [26]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Sulindac and Escitalopram. Depression [6A70-6A7Z] [26]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Sulindac and Desvenlafaxine. Depression [6A70-6A7Z] [26]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Sulindac and Clomipramine. Depression [6A70-6A7Z] [26]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Sulindac and PMID28870136-Compound-49. Discovery agent [N.A.] [30]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Sulindac and Cannabidiol. Epileptic encephalopathy [8A62] [18]
Ethacrynic acid DM60QMR Moderate Antagonize the effect of Sulindac when combined with Ethacrynic acid. Essential hypertension [BA00] [31]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Sulindac and Tazemetostat. Follicular lymphoma [2A80] [20]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Sulindac and Avapritinib. Gastrointestinal stromal tumour [2B5B] [18]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Sulindac and Sulfinpyrazone. Gout [FA25] [20]
Eplerenone DMF0NQR Moderate Antagonize the effect of Sulindac when combined with Eplerenone. Heart failure [BD10-BD1Z] [32]
Chlorothiazide DMLHESP Moderate Antagonize the effect of Sulindac when combined with Chlorothiazide. Heart failure [BD10-BD1Z] [31]
Furosemide DMMQ8ZG Moderate Antagonize the effect of Sulindac when combined with Furosemide. Heart failure [BD10-BD1Z] [31]
Bumetanide DMRV7H0 Moderate Antagonize the effect of Sulindac when combined with Bumetanide. Heart failure [BD10-BD1Z] [31]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Sulindac and Brentuximab vedotin. Hodgkin lymphoma [2B30] [33]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Sulindac and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [34]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Sulindac and Mipomersen. Hyper-lipoproteinaemia [5C80] [35]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Sulindac and Teriflunomide. Hyper-lipoproteinaemia [5C80] [15]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Sulindac and BMS-201038. Hyper-lipoproteinaemia [5C80] [36]
Indapamide DMGN1PW Moderate Antagonize the effect of Sulindac when combined with Indapamide. Hypertension [BA00-BA04] [31]
Trichlormethiazide DMHAQCO Moderate Antagonize the effect of Sulindac when combined with Trichlormethiazide. Hypertension [BA00-BA04] [31]
Hydrochlorothiazide DMUSZHD Moderate Antagonize the effect of Sulindac when combined with Hydrochlorothiazide. Hypertension [BA00-BA04] [37]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Sulindac and Dipyridamole. Hypertension [BA00-BA04] [20]
Potassium chloride DMMTAJC Moderate Increased risk of hyperkalemia by the combination of Sulindac and Potassium chloride. Hypo-kalaemia [5C77] [38]
Fludrocortisone DMUDIR8 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [14]
Balsalazide DM7I1T9 Moderate Increased risk of nephrotoxicity by the combination of Sulindac and Balsalazide. Indeterminate colitis [DD72] [13]
Ibandronate DM0QZBN Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Ibandronate. Low bone mass disorder [FB83] [18]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Sulindac and Porfimer Sodium. Lung cancer [2C25] [39]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Sulindac and Idelalisib. Mature B-cell leukaemia [2A82] [40]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Sulindac and Acalabrutinib. Mature B-cell lymphoma [2A85] [41]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Sulindac and Clofarabine. Mature B-cell lymphoma [2A85] [18]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Sulindac and Ibrutinib. Mature B-cell lymphoma [2A85] [42]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Sulindac and Ponatinib. Mature B-cell lymphoma [2A85] [43]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Sulindac and Exjade. Mineral absorption/transport disorder [5C64] [44]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Sulindac and Panobinostat. Multiple myeloma [2A83] [16]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Deflazacort. Muscular dystrophy [8C70] [14]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Sulindac and Ruxolitinib. Myeloproliferative neoplasm [2A20] [20]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Sulindac and Dasatinib. Myeloproliferative neoplasm [2A20] [45]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Sulindac and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [46]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Sulindac and Prasugrel. Myocardial infarction [BA41-BA43] [18]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Sulindac and Vorapaxar. Myocardial infarction [BA41-BA43] [47]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Sulindac and Tirofiban. Myocardial infarction [BA41-BA43] [48]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Sulindac and Sibutramine. Obesity [5B80-5B81] [26]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Sulindac and Dexfenfluramine. Obesity [5B80-5B81] [26]
Polythiazide DMCH80F Moderate Antagonize the effect of Sulindac when combined with Polythiazide. Oedema [MG29] [31]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Sulindac and MK-4827. Ovarian cancer [2C73] [18]
Aspirin DM672AH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Aspirin. Pain [MG30-MG3Z] [49]
Prednisone DM2HG4X Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Prednisone. Postoperative inflammation [1A00-CA43] [14]
Hydrocortisone DMGEMB7 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Hydrocortisone. Postoperative inflammation [1A00-CA43] [14]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Sulindac and Epoprostenol. Pulmonary hypertension [BB01] [50]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Sulindac and Iloprost. Pulmonary hypertension [BB01] [50]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Sulindac and Everolimus. Renal cell carcinoma [2C90] [51]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Sulindac and Temsirolimus. Renal cell carcinoma [2C90] [51]
Gatifloxacin DMSL679 Moderate Additive CNS stimulant effects by the combination of Sulindac and Gatifloxacin. Respiratory infection [CA07-CA4Z] [21]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [14]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Sulindac and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [18]
Prednisolone DMQ8FR2 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [14]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Pitolisant. Somnolence [MG42] [18]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Sulindac and Naltrexone. Substance abuse [6C40] [52]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Sulindac and Apixaban. Thrombosis [DB61-GB90] [18]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Sulindac and Cangrelor. Thrombosis [DB61-GB90] [20]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Sulindac and Brilinta. Thrombosis [DB61-GB90] [18]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Sulindac and Cabozantinib. Thyroid cancer [2D10] [53]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Sulindac and Sirolimus. Transplant rejection [NE84] [51]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Sulindac and Tacrolimus. Transplant rejection [NE84] [51]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Sulindac and Tolbutamide. Type 2 diabetes mellitus [5A11] [17]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Sulindac and Chlorpropamide. Type 2 diabetes mellitus [5A11] [17]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Sulindac and Olsalazine. Ulcerative colitis [DD71] [13]
Cinoxacin DM4EWNS Moderate Additive CNS stimulant effects by the combination of Sulindac and Cinoxacin. Urinary tract infection [GC08] [21]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Sulindac and Plazomicin. Urinary tract infection [GC08] [22]
Nalidixic acid DMRM0JV Moderate Additive CNS stimulant effects by the combination of Sulindac and Nalidixic acid. Urinary tract infection [GC08] [21]
Triamcinolone DM98IXF Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [14]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Sulindac and Betrixaban. Venous thromboembolism [BD72] [54]
⏷ Show the Full List of 113 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Carmellose sodium E00625 Not Available Disintegrant
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Sulindac 150 mg tablet 150 mg Oral Tablet Oral
Sulindac 200 mg tablet 200 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Sulindac FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5425).
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
8 Fluo-cAMP is transported by multidrug resistance-associated protein isoform 4 in rat choroid plexus. J Neurochem. 2010 Oct;115(1):200-8.
9 Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
10 Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
11 Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
12 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
13 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
14 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
15 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
16 Cerner Multum, Inc. "Australian Product Information.".
17 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
18 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
20 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
21 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
22 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
23 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
24 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
25 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
26 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
27 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
28 Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
29 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
30 Canadian Pharmacists Association.
31 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
32 Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
33 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
34 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
35 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
36 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
37 McCarthy JT, Torres VE, Romero JC, et al "Acute intrinsic renal failure induced by indomethacin." Mayo Clin Proc 57 (1982): 289-96. [PMID: 6952058]
38 Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
39 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
40 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
41 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
42 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
43 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
44 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
45 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
46 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
47 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
48 Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
49 Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
50 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
51 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
52 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
53 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
54 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.